You are here

Article Text

Article menu
Download PDFPDF
Prognosis
Cohort study
Need remains for evidence-based reassurance for absence of bilirubin neurotoxicity with severe hyperbilirubinaemia
  1. Vinod K Bhutani
  1. Department of Pediatrics, Stanford University, Palo Alto, California, USA
  1. Correspondence to : Professor Vinod K Bhutani
    Department of Pediatrics, Stanford University, 750 Welch Rd, #315, Palo Alto, CA 94304, USA; bhutani{at}stanford.edu

http://dx.doi.org/10.1136/eb-2012-101058

Statistics from Altmetric.com

    Commentary on: Vandborg PK, Hansen BM, Greisen G, et al. Follow-up of neonates with total serum bilirubin levels ≥ 25 mg/dL: a Danish population-based study. Pediatrics 2012;130:61–6.OpenUrlAbstract/FREE Full Text

    Context

    Bilirubin-induced neurological dysfunction and its contextual relationship to severity of neonatal hyperbilirubinaemia has been a subject of long-standing debate. Vandborg and colleagues report no evidence of developmental delay, using a parent-centred ‘Ages and Stages Questionnaire’ (ASQ) survey, for a specific cohort of children (age 1 and 5 years) with antecedent severe hyperbilirubinaemia.

    Methods

    This was a controlled descriptive follow-up of 250 047 live-births in Denmark (2004–2007) that is linked through national registries to medical laboratory databases. The review identified 258 infants with severe hyperbilirubinaemia which was defined as at least one measure of total serum bilirubin (TSB) level ≥25 mg/dl (428 μmol/l) during the first 3 weeks after birth. The ASQ method evaluated child development and performance …

    View Full Text

    Footnotes

    • Competing interests None.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions